Renal toxicity of protease inhibitors

Ali J. Olyaei, Angelo M. DeMattos, William M. Bennett

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Introduction of several classes of antiviral agents for the treatment of immunodeficiency virus has led to increased survival and improved quality of life for patients with HIV infection. Protease inhibitors have become the mainstays of current therapy in patient with AIDS. Renal intolerance of indinavir is a rare but important complication in HIV positive patients. The renal function of patients receiving indinavir should be closely monitored. Benign and asymptomatic crystalluria occurs in 4-13% of HIV positive patients. Several cases of acute renal failure, renal atrophy and interstitial nephritis have also been reported. A hydration protocol consisting of one to two liters of fluid should be initiated three hours after each indinavir dose. If significant renal insufficiency persists, temporary indinavir withdrawal or switching to another protease inhibitor should be considered. (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish (US)
Pages (from-to)473-476
Number of pages4
JournalCurrent opinion in nephrology and hypertension
Issue number5
StatePublished - 2000

ASJC Scopus subject areas

  • Internal Medicine
  • Nephrology


Dive into the research topics of 'Renal toxicity of protease inhibitors'. Together they form a unique fingerprint.

Cite this